Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

This study intends to explore the role of PD1/PDL1 antibody with selective combination of Sintilimab, IBI310 and Lenvatinib in organ preservation in non-metastatic dMMR/MSI-H gastric or colon cancers with mismatch repair deficiency or high microsatellite instability

Trial Details

NCT ID
NCT06580574
Phase
PHASE2
Sponsor
Peking University
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • PD1/PDL1 antibody monotherapy, up to 24 weeks
  • Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks
  • Radical surgery
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Subjects are able to comprehend the informed consent form, and voluntarily sign the informed consent form.
  • Subjects are ≥18 years old on the day of signing the informed consent form, with no gender restrictions.
  • Histologically confirmed gastric cancer or colon cancer, without distant metastasis based on CR or MR.
  • ECOG performance status of 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →